tiprankstipranks
Avenue Therapeutics reports Q1 EPS ($15.40) vs ($101.57) last year
PremiumThe FlyAvenue Therapeutics reports Q1 EPS ($15.40) vs ($101.57) last year
6M ago
Avenue Therapeutics files to sell 1.42M shares of common stock for holders
Premium
The Fly
Avenue Therapeutics files to sell 1.42M shares of common stock for holders
7M ago
Avenue Therapeutics trading resumes
Premium
The Fly
Avenue Therapeutics trading resumes
7M ago
Avenue Therapeutics granted extension for Nasdaq compliance
PremiumThe FlyAvenue Therapeutics granted extension for Nasdaq compliance
8M ago
Avenue Therapeutics to presents BAER-101 preclinical data at ASENT meeting
Premium
The Fly
Avenue Therapeutics to presents BAER-101 preclinical data at ASENT meeting
9M ago
ATXI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ATXI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
9M ago
Avenue Therapeutics reaches final agreement with FDA for Phase 3 safety study
PremiumThe FlyAvenue Therapeutics reaches final agreement with FDA for Phase 3 safety study
11M ago
Avenue announces completion of enrollment in Phase 1b/2a trial of AJ201
Premium
The Fly
Avenue announces completion of enrollment in Phase 1b/2a trial of AJ201
11M ago
Avenue Therapeutics initiated yesterday with a Buy at Maxim
Premium
The Fly
Avenue Therapeutics initiated yesterday with a Buy at Maxim
12M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100